Patient Derived Xenograft (PDX) Models Market Outlook
The Global Patient Derived Xenograft (PDX) Models Market was valued at USD 113.5 Million in 2019 and is anticipated to reach 283.3 Million by 2027, expanding at a CAGR of 14.5% during the forecast period. Patient-derived xenografts (PDX) are models of cancer in which the cells from a patient’s tumor are inserted into an immune deficient or humanized mouse.
PDX models simulate that human tumor biology is allowing for natural cancer progression and offers translational research for calculating the desired result. Patient-derived xenograft (PDX) mouse models includes the insertion of fresh human tumor samples directly into the immune-deficient mice by surgery. Xenograft animal models are required for testing the effectiveness of medicines and are mostly required in drug advancement for cancer, diabetes, infections, etc.
Gene expression in tumors is maintained by sequential path of tumors from mouse to mouse. These models support research for tumor biology and pharmacology deprived of manual influence of cell cultures and are usually used in modified cancer therapy, drug enlargement and clinical tests. PDX models show advanced predictive values for clinical results than cell line‑derived xenograft models and hereditarily engineered mouse models.
Patient Derived Xenograft (PDX) Models Market Dynamics
The market is driven by factors such as Rising governments support for pharmaceutical and biotechnology industries, growing demand for personalized medicines, increasing R&D activities by pharmaceutical and biotechnology companies, surging number of preclinical studies for developing anti-cancer drugs for solid tumors.
Conversely, high cost of personalized PDX models, implementation of stringent guidelines on the use of animal models in cancer research. Rising demand for humanized PDX models is one the major factors anticipated to create lucrative opportunities in the market.
Patient Derived Xenograft (PDX) Models Market Segmental Outlook
Based on types, the Global Patient Derived Xenograft (PDX) Models Market is fragmented into mice models and rat models. Mice models segment is anticipated to hold the largest market share during the forecast period. Ease of procurement, manipulation, and the minimum facilities required for keeping mice models under observation in comparison to rats is driving the PDX models market.
Rising development of biotechnological goods and new medical devices is expected to boost the global patient-derived xenograft (PDX) market. New competitive market players bringing innovative healthcare solutions is anticipated to grow the preclinical testing market, which is expected to increase the demand for rat models. Introduction of immunodeficient rats drives the use of rat models in the PDX models market. Rat models segment is anticipated to boost at a substantial growth rate during the forecast period. Factors which drives this market consists of the larger size of rats, which enhances surgical manipulation.
On the basis of tumor types, the global patient-derived xenografts (PDX) models market is segmented into gynecological tumor models, gastrointestinal tumor models, urological tumor models, respiratory tumor models, hematological tumor models, and other tumor models. The gastrointestinal tumor models segment is anticipated to dominate the global patient-derived xenografts (PDX) models market, due to rising number of gastrointestinal tumor models and growing gastrointestinal tumor research in academic & research institutions and contract research organizations (CROs).
The respiratory tumor model segment is expected to grow at the highest rate during the forecast period. Factors attributing to the growth of the segment includes increasing research activities in the oncology field and growing focus of competitive market players on generating lung cancer PDX models, due to increasing number of cancer cases. Funds for companies involved in cancer research are anticipated to grow at a rapid pace during forecast period for the global patient-derived xenografts (PDX) models market.
Based on applications, the global patient-derived xenografts (PDX) models market is fragmented into preclinical drug development, biomarker analysis, and basic cancer research. Preclinical drug development segment is anticipated to reach the maximum growth rate in the PDX models market during the forecast period. Compound annual growth rate of this segment is attributed to increasing number of clinical tests.
The basic cancer research and preclinical drug development segment accounts for a large market share of the global PDX models market. The segment is important, due to rising number of research activities in the oncology drug research field. The basic cancer research disease segment is anticipated to grow at a substantial rate, due to increasing adoption of PDX models for basic cancer research. Basic cancer research is the characterization of cancer biology and exploring mechanisms that are involved for prediction or having a knowledge of cancer.
Based on end-users, the global patient-derived xenograft (PDX) models is fragmented into Pharmaceutical & Biotechnology Companies, Contract Research Organizations (CROs), and Academic & Research Institutions. The academic & research organizations segment dominates the market, as the usage of PDX models is growing for basic cancer research and characterization of cancer biology, tumorigenesis, and metastasis.
The contract research organizations segment is anticipated to grow at a high CAGR during the forecast period. Market growth rate in this segment are attributed to rising number of pharmaceutical companies, which outsource preclinical studies to CROs. The pharmaceutical and biotechnology companies segment is growing at a rapid pace, owing to the boost provided by the ongoing pandemic.
Market players are focusing on developing new and efficient products to cater to the growing needs of the market. The segment is predicted to grow at a substantial rate.
Regional Outlook
Based on regions, the global Patient Derived Xenograft (PDX) Models market is segregated into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America accounts for a major share of the market, followed by Europe. The market in North America is projected to expand at a significant CAGR during the forecast period, owing to increasing preclinical activities by CROs and pharmaceutical companies and rapid growth in onco-immunology research are some of the factors driving the market in North America.
Moreover, the market in Asia Pacific is expected to grow due to rising prevalence of cancer and increasing government expenditure on pharmaceutical R&D. It is also estimated to grow at the highest CAGR in the PDX models market during the forecast period, mainly owing to factors such as increasing trend of outsourcing drug discovery services, and growing life sciences research.
Key Benefits for Industry Participants & Stakeholders
- In-depth Analysis of the Global Patient Derived Xenograft (PDX) Models Market
- Historical, Current and Projected Market Size in terms of Value and Volume
- Potential & Niche Segments and Regions Exhibiting Promising Growth Covered
- Industry Drivers, Restraints and Opportunities Covered in the Study
- Recent Industry Trends and Developments
- Competitive Landscape & Strategies of Key Players
- Neutral Perspective on Global Patient Derived Xenograft (PDX) Models Market Performance
Segments
By Type
By Tumor Type
- Gastrointestinal Tumor Models
- Gynecological Tumor Models
- Respiratory Tumor Models
- Urological Tumor Models
- Hematological Tumor Models
- Others
By Application
- Preclinical Drug Development
- Biomarker Analysis
- Basic Cancer Research
By End-user
- Pharmaceutical & Biotechnology Companies
- Contract Research Organizations (CROs)
- Academic & Research Institutions
By Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
Key Players
- Abnova Corporation
- Aragen Bioscience, a GVKBIO Company
- Bioduro
- Champions Oncology, Inc.
- Charles River Laboratories
- Envigo
- EPO Berlin-Buch GmbH
- Explora BioLabs
- Hera Biolabs
- NexusPharma
- Oncodesign
- THE JACKSON LABORATORY
- Urosphere
- WuXi AppTec
- Xentech
Competitive Landscape
- Top players in the market include THE JACKSON LABORATORY, WuXi AppTec, Envigo, Oncodesign, and Charles River Laboratories. These companies are considered as key manufacturers of Patient Derived Xenograft (PDX) Models based on their revenue, research development (R&D) activities, product offerings, regional presence, and supply chain management system.
- The players are adopting key strategies such as acquisition, collaborations, and geographical expansion where potential opportunity for the Patient Derived Xenograft (PDX) Models market.
- On March 02, 2021, Explora BioLabs launched two facilities in San Diego, in the US. The launch of these facilities is expected to expand Explora BioLabs’s footprints in San Diego from seven to nine on-demand vivaria.
- On February 25, 2021, Charles River Laboratories, entered into a strategic partnership with Kibur Medical to offer exclusive access to its implantable microdevice (IMD) for in vivo preclinical oncology studies. Through this partnership, together with leading expertise in early-stage preclinical testing, researchers can utilize the Kibur technology to perform in vivo testing of multiple doses and multiple combinations of oncology or immune-oncology therapies in small cohorts of patient-derived xenograft (PDX), cell-line derived or syngeneic models.
- In January 2021, Endo International plc launched Authorized Generic Version of Amitiza (lubiprostone) Capsules in the US.